tirzepatide cvot cardiovascular event risk assessment: a pre-specified meta-analysis Tirzepatide's innovative applications in the

Beyond glycemic control, GLP-1 medications slow gastric emptying, which prolongs the sensation of fullness after eating and contributes to reduced appetite

The timing varies based on individual factors like hydration status and electrolyte balance

Skipping protein, staying dehydrated, or drastically undereating can also interfere with healthy weight loss

Your risk for getting low blood sugar may be higher if you use Mounjaro with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin

It slows stomach emptying, and this effect is strongest after the first dose and after each dose increase